Good morning, good afternoon and good evening,
On COVID-19, globally reported cases have increased nearly 30% over the past two weeks.
Four out of six of the WHO sub-regions saw cases increase in the last week.
In Europe and America, BA.4 and BA.5 are driving waves. In countries like India a new sub lineage of BA.2.75 has also been detected, which we’re following.
Compounding the challenge are a number of factors:
First, testing has reduced dramatically in many countries. This obscures the true picture of an evolving virus and the real burden of COVID-19 disease globally.
It also means that treatments are not given early enough to prevent serious illness and/or death.
Second, new treatments, especially promising new oral antivirals, are still not reaching low- and low-middle income countries, depriving whole populations that need them.
Third, as the virus evolves, vaccines protection – while still really effective at preventing serious disease and death – does wane.
Decreasing immunity underscores the importance of boosters, especially for the most at-risk.
Fourth, each wave of the virus leaves more people with long-COVID or post-COVID condition.
This obviously impacts individuals and their families but it also puts an extra burden on health systems, the wider economy and society-at-large.
These challenges require action at a global, national and local level.
Governments, scientists, manufacturers, WHO and citizens themselves all have their part to play.
Essential steps to take include:
One, vaccinate and boost those at most risk. This includes older people, people with chronic illnesses, the immunocompromised and health workers. Then build up the wall of immunity throughout the population.
Two, make new oral antivirals and other treatments available to all.
Working with Global Fund and UNICEF, WHO has developed an allocation mechanism to support countries as antivirals become available.
So far, 20 countries have accepted allocations of Molnupiravir, which has moved into distribution.
For Nirmatrelvir-Ritonavir, – or Paxlovid – 43 countries have expressed interest.
However, our organizations are still trying to finalize with Pfizer the appropriate terms and conditions for low- and middle-income countries.
This is delaying access and some countries may choose to wait for a generic version of the antiviral, probably available only early 2023 and this will cost lives.
I call on Pfizer to work closely with health agencies and countries to ensure its new oral antiviral is available quickly and effectively.
Third, especially if you’re in a place where cases are on the rise, use tried and tested public health measures to mitigate risk.
For example, if you’re in a crowded place or inside and there’s poor ventilation, put on a mask. And if you’re sick, and you can, stay home.
Fourth, it is crucial to accelerate research and development into next generation vaccines, tests and treatments.
WHO is working with scientists and researchers around the world to make this happen.
Through the Solidarity Trials, WHO can ensure maximum efficiency of clinical trials so that new tools are developed quicker.
We don’t know how the next variant will be like. This requires that we apply the tools we have now and that we develop the next generation of counter measures quickly.
Fifth, we continue to work to strengthen the global health architecture for health emergency and response at all levels.
We welcome the news about the creation of the financial intermediary fund (FIF), which will focus on strengthening pandemic prevention, preparedness, and response capacities. It will operate at a national, regional, and global level, with a focus on low- and middle-income countries.
WHO and the World Bank will take the design forward with the founding donors and broader stakeholders.
We hope the fund will expand and that this will become an important component of a comprehensive financing solution for health emergencies.
Also, it is important that the pandemic accord process continues at pace.
This remains a generational opportunity to improve how countries prepare for and respond to new pathogens.
On monkeypox, I continue to be concerned by the scale and spread of the virus.
Across the world, there has now been more than 6000 cases recorded in 58 countries.
Testing remains a challenge and it’s highly probable that there are a significant number of cases not being picked up.
Europe is the current epicentre of the outbreak, recording more than 80 percent of cases globally.
In Africa, cases are appearing in countries not previously affected and record numbers are being recorded in places which have previous experience with monkeypox.
My teams are following the data closely, I plan to reconvene the Emergency Committee so they are updated on the current epidemiology and evolution of the outbreak, and implementation of counter measures.
I will bring them together during the week of 18 July or sooner if needed.
WHO is working with countries and vaccine manufacturers to coordinate the sharing of vaccine, which are currently scarce and need to be accessible to the most at risk people.
WHO is also working closely with civil society and LGBTIQ+ community, especially to break the stigma around the virus and spread information so people can protect themselves.
I want to particularly commend those that are sharing videos online via social media channels talking about their symptoms and experiences with monkeypox.
This is a positive way to break down the stigma about a virus that can affect anyone.
Finally, in Syria, the humanitarian needs are at their highest level since the war started 11 years ago.
WHO works across the country to provide lifesaving health support.
In the northwest of the country, some 4.4 million people, including more than 3.5 million women and children, are in need of humanitarian assistance.
They depend on the cross-border access for their healthcare, their vaccines and medicines.
We hope the Security Council will continue to find agreement to preserve the health and welfare of this highly vulnerable population.
On The ACT Accelerator
4 July 2022
WHO Director-General Dr Tedros Adhanom Ghebreyesus has welcomed contributions from Norway and Sweden to the ACT-Accelerator, which have taken both countries over their ‘fair share’ allocation.
Contributions of US$ 340 million from Norway and US$ 300 million from Sweden will accelerate efforts to get vaccines into arms, facilitate access to new treatments and ensure health systems can meet the challenges of the COVID-19 pandemic.
Norway and Sweden join Germany in having exceeded their fair share for ACT-A’s 2021/22 budget, with Canada pledging to do the same. ‘Fair share’ calculations are based on the size of a country’s national economy and what they would gain from a faster recovery of the global economy and trade.
In February 2022, President Ramaphosa of South Africa and Prime Minister Støre of Norway – in their roles as co-chairs of the ACT-Accelerator Facilitation Council – made a call to 55 countries to jointly support global efforts to end the COVID-19 crisis and contribute their ‘fair share’ to the ACT-Accelerator agencies’ urgent needs.
These contributions from Norway and Sweden reinforce the strong support that both countries have provided to the ACT-Accelerator since its inception in 2020.
The ACT-Accelerator now faces a funding gap of US$ 11.2 billion, having received contributions totaling US$ 5.6 billion for the 2021/22 budget.
WHO Director-General Dr Tedros Adhanom Ghebreyesus said: “I wish to commend Norway and Sweden for their commitment towards the vital work of the ACT-Accelerator. We call on other countries to follow their lead in contributing their fair share, and get COVID-19 vaccines, tests and treatments to those who need them most. We have made tremendous progress in reducing mortality and transmission. But cases are still on the rise in 110 countries. Our job is not over. We must ensure that all countries are equipped to fight future waves of COVID-19.”
Please Visit Our Sponsors